Since stimulation of TLR4 induces Nrf2 nuclear translocation as well as its downstream antioxidant enzyme HO-1 in myeloma PCs, the current study supports the notion that TLR4 and HO-1 signaling pathways, both upregulated after BTZ treatment, activated each other. The gene discussed is TLR4; the disease is plasma cell myeloma.